Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tramadol hydrochloride, quantity: 200 mg - tablet, modified release - excipient ingredients: magnesium stearate; macrogol 6000; titanium dioxide; hypromellose; colloidal anhydrous silica; microcrystalline cellulose; lactose monohydrate; propylene glycol; iron oxide red; iron oxide black; purified talc; quinoline yellow aluminium lake; iron oxide yellow - tramal sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long term treatment. tramal sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. tramal sr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tramadol hydrochloride, quantity: 150 mg - tablet, modified release - excipient ingredients: hypromellose; quinoline yellow aluminium lake; microcrystalline cellulose; purified talc; lactose monohydrate; magnesium stearate; propylene glycol; iron oxide red; colloidal anhydrous silica; macrogol 6000; titanium dioxide - tramal sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long term treatment. tramal sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. tramal sr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide yellow; magnesium oxide; croscarmellose sodium; microcrystalline cellulose; povidone; lactose monohydrate - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indicated in patients with unstable angina pectoris (see clinical trials). pravachol is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; magnesium stearate; povidone; microcrystalline cellulose; lactose monohydrate; iron oxide yellow; magnesium oxide - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indicated in patients with unstable angina pectoris (see clinical trials). pravachol is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; magnesium stearate; povidone; microcrystalline cellulose; lactose monohydrate; iron oxide yellow; magnesium oxide - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. apx-pravastatin is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. apx-pravastatin is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. apx-pravastatin is indicated in patients with unstable angina pectoris (see clinical trials). apx-pravastatin is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide yellow; magnesium oxide; croscarmellose sodium; microcrystalline cellulose; povidone; lactose monohydrate - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. apx-pravastatin is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. apx-pravastatin is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. apx-pravastatin is indicated in patients with unstable angina pectoris (see clinical trials). apx-pravastatin is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - paroxetine hydrochloride, quantity: 22.2 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; mannitol; titanium dioxide; sodium starch glycollate; colloidal anhydrous silica; hypromellose; copovidone; purified talc - paroxetine is indicated for the treatment of : - major depression and for the prevention of relapse of depressive symptoms - obsessive compulsive disorder (ocd) and prevention of relapse of ocd - panic disorder and for the prevention of relapse of panic disorder - social anxiety disorder/social phobia - general anxiety disorder - post-traumatic stress disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

well herb pty ltd - anemarrhena asphodeloides,angelica dahurica,chrysanthemum indicum,forsythia suspensa,glycyrrhiza uralensis,magnolia obovata,phellodendron amurense,platycodon grandiflorus,saposhnikovia divaricata,schisandra chinensis,schizonepeta tenuifolia,xanthium sibiricum -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun herbal pty ltd - cinnamomum cassia, quantity: 12.99 mg (equivalent: cinnamomum cassia, qty 28.13 mg; equivalent: coumarin, qty 0.31 microgram); scutellaria baicalensis, quantity: 12.99 mg (equivalent: scutellaria baicalensis, qty 28.13 mg); schizonepeta tenuifolia, quantity: 12.99 mg (equivalent: schizonepeta tenuifolia, qty 28.13 mg); mentha haplocalyx, quantity: 21.66 mg (equivalent: mentha haplocalyx, qty 46.88 mg); morus alba, quantity: 21.66 mg (equivalent: morus alba, qty 46.88 mg); angelica dahurica, quantity: 12.99 mg (equivalent: angelica dahurica, qty 28.13 mg); chrysanthemum sinense, quantity: 17.33 mg (equivalent: chrysanthemum sinense, qty 37.5 mg); saposhnikovia divaricata, quantity: 12.99 mg (equivalent: saposhnikovia divaricata, qty 28.125 mg); anemone altaica, quantity: 12.99 mg (equivalent: anemone altaica, qty 28.13 mg); xanthium sibiricum, quantity: 12.99 mg (equivalent: xanthium sibiricum, qty 28.13 mg); magnolia liliflora, quantity: 21.66 mg (equivalent: magnolia liliflora, qty 46.88 mg) - pill - excipient ingredients: soluble maize starch - traditionally used in chinese medicine to release exterior/exogenous wind-coldness ; traditionally used in chinese medicine to dispel/expel/extinguish/disperse/clear wind-heat ; traditionally used in chinese medicine to decongestant/relieve nasal congestion

Australia - English - Department of Health (Therapeutic Goods Administration)

sun herbal pty ltd - cinnamomum cassia, quantity: 22.387 mg (equivalent: cinnamomum cassia, qty 135 mg; equivalent: coumarin, qty 1.69 microgram); scutellaria baicalensis, quantity: 22.387 mg (equivalent: scutellaria baicalensis, qty 135 mg); ledebouriella seseloides, quantity: 22.387 mg (equivalent: ledebouriella seseloides, qty 135 mg); schizonepeta tenuifolia, quantity: 22.387 mg (equivalent: schizonepeta tenuifolia, qty 135 mg); mentha haplocalyx, quantity: 37.312 mg (equivalent: mentha haplocalyx, qty 225 mg); morus alba, quantity: 37.312 mg (equivalent: morus alba, qty 225 mg); angelica dahurica, quantity: 22.387 mg (equivalent: angelica dahurica, qty 135 mg); chrysanthemum sinense, quantity: 29.85 mg (equivalent: chrysanthemum sinense, qty 180 mg); anemone altaica, quantity: 22.387 mg (equivalent: anemone altaica, qty 135 mg); xanthium sibiricum, quantity: 22.387 mg (equivalent: xanthium sibiricum, qty 135 mg); magnolia liliflora, quantity: 37.312 mg (equivalent: magnolia liliflora, qty 225 mg) - capsule, hard - excipient ingredients: titanium dioxide; hydrolysed gelatin; soluble maize starch - traditionally used in chinese medicine to dispel/expel/extinguish/disperse/clear exogenous wind ; traditionally used in chinese medicine to unblock/clear nasal passages